Efficacy results achieved with TYMLOS were MAINTAINED
with sequential therapy1,2

New vertebral fractures: Risk reduction achieved with TYMLOS
was maintained after transitioning to open-label alendronate1

Percentage of postmenopausal women with osteoporosis with new vertebral fractures at 25 and 43 months1,2*

Percentage of postmenopausal women with osteoporosis with new vertebral fractures graph

TYMLOS or placebo for 18 months, followed by 1 month of no treatment, then up to 24 months of open-label alendronate.3

P<0.0001.1

Results reported in the modified ITT, which included patients who had both pretreatment and posttreatment spine radiographs.1,2

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.4

At least fewer women in the TYMLOS→ open-label alendronate group experienced new vertebral fractures
versus those in the placebo→ open-label alendronate group at 43 months2

See nonvertebral fracture dataMinus iconPlus icon

Nonvertebral fractures: Risk reduction achieved with TYMLOS was maintained after transitioning to open-label alendronate2

Cumulative incidence of nonvertebral
fractures* over 43 months1,2,4†

Cumulative incidence of nonvertebral fracture graph

Nonvertebral fractures excluded those of the sternum, patella, toes, fingers, skull, and face, and those associated with high trauma.2

TYMLOS or placebo for 18 months, followed by 1 month of no treatment, then up to 24 months of open-label alendronate; P value based on the log-rank test.2,3

P=0.017.1

Results reported in the extension study ITT population, which included patients randomized in the efficacy study.2

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.4

See change in BMDMinus iconPlus icon

BMD increases achieved with TYMLOS were maintained after transitioning to open-label alendronate2

In a 25-month analysis*, significant increases in BMD at the lumbar spine, total hip, and femoral neck achieved with
TYMLOS at 18 months were maintained after transitioning to 6 months of open-label alendronate (P<0.0001 at all sites)1

Patients receiving 18 months of TYMLOS maintained at least a two-fold increase in BMD when followed by 24 months
of open-label alendronate versus those who transitioned from placebo1,4

Patients receiving 18 months of TYMLOS maintained at least a two-fold increase in BMD when followed by 24 months of open-label alendronate versus those who transitioned from placebo1,4

Average percentage change from baseline in BMD in postmenopausal women osteoporosis graph

Mean percent change from baseline in BMD in postmenopausal women with osteoporosis at 43 months4*

TYMLOS or placebo for 18 months, followed by 1 month of no treatment, then up to 24 months of open-label alendronate.1

Results reported in ITT population, which included patients enrolled in the extension study; mean percentage change in BMD was LOCF.4

BMD captured with DXA scans.4

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.4

Find useful resources and
tools for
your office

References: 1. TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2018. 2. Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949-2957. 3. Cosman F, Miller PD, Williams GC, et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc. 2017;92(2):200-210. 4. Data on file. Radius Health, Inc; Waltham, MA.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2019 Radius Health, Inc.   All rights reserved.    10/19.   TYM-US-02916

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2019 Radius Health, Inc.
All rights reserved. 10/19.
TYM-US-02916

Back to Top